Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GAMIDA CELL LTD.

(GMDA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Gamida Cell Ltd. - GMDA

11/15/2021 | 09:48am EST

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gamida Cell Ltd. ("Gamida" or the "Company") (NASDAQ: GMDA).  Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Gamida and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On November 11, 2021, Gamida issued a press release providing an update on the Company's Pre-Biologics License Application ("BLA") meeting with the U.S. Food and Drug Administration for omidubicel, the Company's proposed blood cancer treatment.  Specifically, Gamida disclosed that "[t]he FDA requested that Gamida Cell provide revised analysis of the manufacturing data generated at Gamida Cell's wholly-owned commercial manufacturing facility to demonstrate the comparability to the omidubicel that was produced at the clinical manufacturing sites for the Phase 3 study", a development that the Company acknowledged would bring a "delay in timing to bring omidubicel to patients after a potential FDA approval[.]" 

On this news, Gamida's stock price fell $0.44 cents, or 11.11% percent, to close at $3.52 per share on November 11, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-gamida-cell-ltd---gmda-301423617.html

SOURCE Pomerantz LLP


© PRNewswire 2021
All news about GAMIDA CELL LTD.
01/19Gamida Cell Plans Rolling Submission of Biologics License Application for Bone Marrow T..
MT
01/19Gamida Cell to Begin Biologics License Application Submission for Omidubicel
DJ
01/19GAMIDA CELL : Provides Update on Omidubicel BLA Submission - Form 8-K
PU
01/19Gamida Cell Provides Update on Omidubicel BLA Submission
BU
01/19GAMIDA CELL LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/19Gamida Cell Provides Update on Omidubicel BLA Submission
CI
01/13GAMIDA CELL : Amendment to Initial Statement of Beneficial Ownership (Form 3/A)
PU
01/07Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy M..
BU
01/03GAMIDA CELL LTD. : Regulation FD Disclosure (form 8-K)
AQ
2021AML Hub increases congress coverage to provide latest developments in acute myeloid leu..
AQ
More news
Analyst Recommendations on GAMIDA CELL LTD.
More recommendations